INNV InnovAge Holding Corp.
Services-Health Services · Nasdaq · SEC CIK 1834376 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.1%
TTM net income YoY151.8%
TTM EPS YoY150.0%
Revenue 3-yr CAGR13.3%
Net income 3-yr CAGR—
Margins
Gross margin23.6%
Operating margin1.4%
Net margin0.9%
FCF margin7.5%
EBITDA margin3.6%
Returns
ROE3.6%
ROA1.7%
ROIC (approx.)5.4%
Asset turnover1.90x
Leverage & solvency
Liabilities / assets48.6%
Debt / equity0.19x
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income9.95x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $989.71M | $853.70M | $763.86M | $688.09M | $698.64M |
| Gross profit | $227.76M | $153.64M | $132.06M | $101.29M | $135.37M |
| SG&A expense | $166.49M | $122.06M | $111.34M | $115.64M | $101.65M |
| Operating income | $2.62M | -$29.76M | -$23.18M | -$49.40M | -$4.41M |
| Interest expense | — | — | — | — | $2.53M |
| Pretax income | $266,000 | -$34.03M | — | — | — |
| Income tax | $949,000 | $1.32M | $1.40M | -$7.24M | $723,000 |
| Net income | -$2.54M | -$30.31M | -$21.34M | -$40.67M | -$6.52M |
| EBITDA | $23.76M | -$10.25M | -$4.23M | -$33.98M | $9.52M |
| EPS (basic) | -0.02 | -0.22 | -0.16 | -0.30 | -0.05 |
| EPS (diluted) | -0.02 | -0.22 | -0.16 | -0.30 | -0.05 |
| Weighted avg. shares (diluted) | 135.70M | 135.39M | 135.90M | 135.59M | 135.52M |
| Balance sheet | |||||
| Cash & equivalents | $97.89M | $64.14M | $56.96M | $127.27M | $184.45M |
| Short-term investments | $43.44M | $41.77M | $45.83M | $46.21M | $0 |
| Receivables | $42.39M | $36.37M | $48.11M | $24.34M | $35.91M |
| Current assets | $214.31M | $176.11M | $173.14M | $215.23M | $240.96M |
| PP&E, net | $166.09M | $168.04M | $193.02M | $192.19M | $176.26M |
| Goodwill | $142.05M | $142.05M | $139.95M | $124.22M | $124.22M |
| Intangibles | $3.22M | $3.88M | $4.54M | $5.20M | $5.86M |
| Total assets | $557.39M | $526.85M | $547.66M | $567.36M | $555.60M |
| Current liabilities | $203.89M | $164.81M | $138.60M | $148.45M | $105.31M |
| Short-term debt | $2.54M | $2.25M | $3.79M | $3.79M | $3.79M |
| Long-term debt | $45.52M | $57.46M | $61.48M | $64.84M | $68.21M |
| Total debt | $48.06M | $59.71M | $65.27M | $68.64M | $72.00M |
| Total liabilities | $288.62M | $263.94M | $247.85M | $252.56M | $201.85M |
| Shareholders' equity | $235.60M | $234.97M | $269.26M | $296.30M | $332.36M |
| Net debt | -$49.83M | -$4.43M | $8.31M | -$58.63M | -$112.44M |
| Shares outstanding | 136.02M | 135.44M | 136.12M | 135.64M | 135.53M |
| Cash flow statement | |||||
| Operating cash flow | $64.71M | $32.87M | -$36.90M | $20.24M | $27.30M |
| Capital expenditure | $14.31M | $6.26M | $7.91M | $23.35M | $38.24M |
| Free cash flow | $50.41M | $26.60M | -$44.81M | -$3.12M | -$10.94M |
| Investing cash flow | -$12.34M | -$5.55M | -$26.37M | -$69.52M | -$40.24M |
| Financing cash flow | -$18.53M | -$19.08M | -$7.03M | -$7.90M | -$6.32M |
| Depreciation & amortization | $21.14M | $19.51M | $18.95M | $15.42M | $13.92M |
| Stock-based compensation | $7.05M | $7.62M | $6.83M | $4.61M | $3.74M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.